CK2-mediated DEK Phosphorylation Drives PBX3 Overexpression: A Core Event in Hematopoietic Stem Cell-to-Leukemia Stem Cell Transformation
Ontology highlight
ABSTRACT:
INSTRUMENT(S):
ORGANISM(S): Mus Musculus (mouse)
TISSUE(S): Stem Cell, Bone Marrow
DISEASE(S): Acute Myeloid Leukemia
SUBMITTER: 
yufei lei
LAB HEAD: Zhe Chen
PROVIDER: PXD068965 | Pride | 2026-07-06
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| XC00039B1DI_DEK_L-GMP_Flag_2.raw | Raw | |||
| XC00039DI_DEK_L-GMP_Flag_1.raw | Raw | |||
| checksum.txt | Txt | |||
| search.zip | Other |
Items per page: 5 1 - 4 of 4 |
Similar Datasets
Project description:LSCs from MLL-AF9-driven Nup214fl/fl and Nup214fl/fl,Tie2-Cre AML mice were sorted, followed by further proteomic assay.
2025-07-26 | PXD054471 | Pride
Project description:To illustrate NUP214-interacting proteins, we performed co-immunoprecipitation (co-IP) followed by mass spectrometry using MLL-AF9-driven LSCs to characterize protein interactomes of NUP214.
2025-07-26 | PXD054438 | Pride
Project description:Amyloid plaque is a pathological hallmark in Alzheimer's disease (AD) brain with their composition associated with dis-ease etiology. Here, we report a photocatalyst, namely AmyCAT, that selectively binds to amyloid fibrils in AD brain tis-sue and undergoes Dexter energy transfer (DET) to catalyze carbene production for amyloid proximity labeling. First, we design the AmyCAT photocatalyst to generally bind different types of amyloids. Second, we energetically match the DET effect in a 12 × 4 photocatalysts-substrates array to activate diazo substrate into reactive carbene by visible green light (530~545 nm). Further, we demonstrate that the optimal AmyCAT probe catalyzes pan-amyloid protein labeling with 30-fold selectivity over folded counterparts. Mechanistic studies confirm the photocatalytic labeling is indeed via DET pro-cess, which tailors the proximity effect for spatially confined amyloid labeling. Finally, we employ the AmyCAT photo-catalyst to label, enrich and profile amyloid plagues in AD brain tissue, revealing key proteins and pathways associated with AD pathological deposition and etiology.
2025-01-23 | PXD060112 | Pride
Project description:The highly metastatic MHCC-97H HCC cell line was orthotopic transplanted into the liver of nude mice to induce orthotopic tumor formation, and lung metastasis was observed. This experimental model not only reproduces the metastasis process of HCC in vivo, but also provides an important biological material for studying the tumor microenvironment and metastasis mechanism. Subsequently, we collected liver cancer tissues, and further conducted in-depth proteomic analysis of the collected liver tumor tissue samples, in order to reveal the key protein expression changes and potential signaling pathway regulation mechanisms during tumor development and metastasis, and lay the foundation for subsequent targeted therapy research.
2026-06-08 | PXD059613 | Pride
Project description:Amyloid plaque is a pathological hallmark in Alzheimer's disease (AD) brain with their composition associated with dis-ease etiology. Here, we report a photocatalyst, namely AmyCAT, that selectively binds to amyloid fibrils in AD brain tis-sue and undergoes Dexter energy transfer (DET) to catalyze carbene production for amyloid proximity labeling. First, we design the AmyCAT photocatalyst to generally bind different types of amyloids. Second, we energetically match the DET effect in a 12 × 4 photocatalysts-substrates array to activate diazo substrate into reactive carbene by visible green light (530~545 nm). Further, we demonstrate that the optimal AmyCAT probe catalyzes pan-amyloid protein labeling with 30-fold selectivity over folded counterparts. Mechanistic studies confirm the photocatalytic labeling is indeed via DET pro-cess, which tailors the proximity effect for spatially confined amyloid labeling. Finally, we employ the AmyCAT photo-catalyst to label, enrich and profile amyloid plagues in AD brain tissue, revealing key proteins and pathways associated with AD pathological deposition and etiology.
2025-01-23 | PXD060111 | Pride
Project description:Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core post-translational events governing LSC formation and maintenance remain elusive. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) versus LSC-enriched population, we identify DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts (PDXs), demonstrate that DEK deficiency impairs LSC maintenance and AML development. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax (Aza/Ven), whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GABPA to drive overexpression of transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining a leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S site), which stabilizes the conformation of the DEK-GABPA complex. We demonstrate CK2 as the upstream kinase that directly phosphorylates DEK-4S site. Importantly, inhibition of DEK phosphorylation through 4S site mutations or treatment with a clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and suppresses the PBX3-mediated leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy in AML.
2025-09-30 | GSE309177 | GEO
Project description:Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core post-translational events governing LSC formation and maintenance remain elusive. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) versus LSC-enriched population, we identify DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts (PDXs), demonstrate that DEK deficiency impairs LSC maintenance and AML development. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax (Aza/Ven), whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GABPA to drive overexpression of transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining a leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S site), which stabilizes the conformation of the DEK-GABPA complex. We demonstrate CK2 as the upstream kinase that directly phosphorylates DEK-4S site. Importantly, inhibition of DEK phosphorylation through 4S site mutations or treatment with a clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and suppresses the PBX3-mediated leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy in AML.
2025-09-30 | GSE309284 | GEO
Project description:Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core post-translational events governing LSC formation and maintenance remain elusive. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) versus LSC-enriched population, we identify DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts (PDXs), demonstrate that DEK deficiency impairs LSC maintenance and AML development. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax (Aza/Ven), whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GABPA to drive overexpression of transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining a leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S site), which stabilizes the conformation of the DEK-GABPA complex. We demonstrate CK2 as the upstream kinase that directly phosphorylates DEK-4S site. Importantly, inhibition of DEK phosphorylation through 4S site mutations or treatment with a clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and suppresses the PBX3-mediated leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy in AML.
2026-04-28 | GSE329270 | GEO
Project description:Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core post-translational events governing LSC formation and maintenance remain elusive. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) versus LSC-enriched population, we identify DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts (PDXs), demonstrate that DEK deficiency impairs LSC maintenance and AML development. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax (Aza/Ven), whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GABPA to drive overexpression of transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining a leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S site), which stabilizes the conformation of the DEK-GABPA complex. We demonstrate CK2 as the upstream kinase that directly phosphorylates DEK-4S site. Importantly, inhibition of DEK phosphorylation through 4S site mutations or treatment with a clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and suppresses the PBX3-mediated leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy in AML.
2026-04-28 | GSE329274 | GEO
Project description:Skeletal muscle atrophy, which is induced by factors such as disuse, spaceflight, certain medications, neurological disorders, and malnutrition, is a global health issue lacking effective treatment. Hindlimb unloading is a commonly used model for muscle atrophy. However, the underlying mechanism of muscle atrophy induced by hindlimb unloading remains unclear, particular from the perspective of myocyte proteome and metabolism. We first used mass spectrometry for proteomic sequencing and untargeted metabolomics to analyze soleus muscle changes in rats with hindlimb unloading. The study found 1052 proteins and 377 metabolites (with MS2 name) differentially expressed between HU group and CON group. Proteins like ACTN3, MYH4, MYBPC2, and MYOZ1, typically found in fast-twitch muscles, were upregulated, along with metabolism-related proteins GLUL, GSTM4, and NDUFS4. Metabolites arachidylcarnitine and 7,8-dihydrobiopterin, and pathways like histidine, taurine, and hypotaurine metabolism were linked to muscle atrophy. Protein and metabolism joint analysis revealed that some pathways such as glutathione metabolism, ferroptosis and lysosome pathways were likely to be involved in soleus atrophy. In this study, we have applied integrated deep proteomic and metabolomic analysis. The upregulation of proteins which are expressed in fast-twitch fibers indicated the conversion of slow-twitch fibers to fast-twitch fibers under HU. Some metabolism-related proteins have been screened out. Besides, some differentially abundant metabolites and pathways revealed the important role of metabolism in the muscle atrophy of soleus. Our study provides insights into the pathogenesis and treatment of muscle atrophy that results from unloading by integrating the proteomics and metabolomics of soleus muscles.
2025-05-07 | PXD057671 | Pride